Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048958 · ClinicalTrials.gov registry record
Cytogenetic Studies in Acute Leukemia and Multiple Myeloma
A clinical trial of Multiple Myeloma and Myelodysplastic Syndrome, sponsored by Alliance for Clinical Trials in Oncology.
- Active
- Registry status
- 9,000
- Enrollment target
- 20
- Study locations
NCT00048958: Active study of Multiple Myeloma and Myelodysplastic Syndrome, sponsored by Alliance for Clinical Trials in Oncology.
NCT00048958 is a study of Multiple Myeloma and Myelodysplastic Syndrome that is active but no longer recruiting, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 9,000 participants, above the 526-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (1611% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00048958, a study of Multiple Myeloma and Myelodysplastic Syndrome, is active but no longer recruiting, sponsored by Alliance for Clinical Trials in Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- 9,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
Chromosomal analysis or the study of genetic differences in patients previously untreated with AML, ALL, MDS or MM may be helpful in the diagnosis and classification of disease. It may also improve the ability to predict the course of disease and the selection of therapy. Institutions must have either an Alliance-approved cytogeneticist or an agreement from an Alliance-approved main member cytogenetics laboratory to enroll a patient on CALGB 8461. The Alliance Approved Institutional Cytogeneticists list is posted on the Alliance for Clinical Trials in Oncology website.
Conditions Studied
Interventions
- GENETIC cytogenetic analysis
Study Locations (20)
Illinois
- Illinois CancerCare - Bloomington - Bloomington
- St. Joseph Medical Center - Bloomington
- Graham Hospital - Canton
- Illinois CancerCare - Canton - Canton
- Illinois CancerCare - Carthage - Carthage
- Memorial Hospital - Carthage
- University of Illinois Cancer Center - Chicago
- University of Chicago Cancer Research Center - Chicago
California
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Camino Medical Group - Treatment Center - Mountain View
- Kaiser Permanente Medical Office -Vandever Medical Office - San Diego
- Naval Medical Center - San Diego - San Diego
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Florida
- Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital - Fort Lauderdale
- Ella Milbank Foshay Cancer Center at Jupiter Medical Center - Jupiter
- CCOP - Mount Sinai Medical Center - Miami Beach
Delaware
- Tunnell Cancer Center at Beebe Medical Center - Lewes
- CCOP - Christiana Care Health Services - Newark
District of Columbia
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center - Washington D.C.
- Washington Cancer Institute at Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,000 participants |
| Start Date | 1984-06 |
What the registry record for NCT00048958 still lists
NCT00048958 is an observational study that tracks outcomes without assigning an intervention. Its 9,000 participants enrollment target places it among the larger protocols in the corpus, above the 526-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (1611% higher).
The record links to 4 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which cytogenetic analysis is the first listed.
NCT00048958 names 20 study sites across 5 states, led by Illinois, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00048958 about?
NCT00048958 is a clinical study titled "Cytogenetic Studies in Acute Leukemia and Multiple Myeloma". Chromosomal analysis or the study of genetic differences in patients previously untreated with AML, ALL, MDS or MM may be helpful in the diagnosis and classification of disease. It may also improve the ability to predict the course of disease and the selection of therapy. Institutions must have eith...
What is the current status of trial NCT00048958?
This trial is currently active not recruiting. The enrollment target is 9,000 participants. The study started on 1984-06.
What conditions does trial NCT00048958 study?
This clinical trial studies the following conditions: Multiple Myeloma, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Acute Leukemia.
What interventions are being tested in trial NCT00048958?
The interventions under investigation include: cytogenetic analysis (GENETIC).
Who is sponsoring clinical trial NCT00048958?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00048958 being conducted?
This trial has 20 study locations across California, Delaware, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00048958's enrollment target sits among peer trials
9,000 4th of 438 higher than 435 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02000089 · 9,000 participants · Phase 3
The Cancer of the Pancreas Screening-5 CAPS5)Study
- NCT05612347 · 8,946 participants · NA
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
- NCT06946355 · 9,119 participants · NA
Food-based Support for Hospitalized Children and Their Families
- NCT05336877 · 8,744 participants
Aveir VR Coverage With Evidence Development Post-Approval Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia